Your browser is no longer supported. Please, upgrade your browser.
JNJ Johnson & Johnson daily Stock Chart
Johnson & Johnson
IndexDJIA S&P500 P/E17.64 EPS (ttm)5.68 Insider Own0.01% Shs Outstand2.77B Perf Week1.07%
Market Cap277.89B Forward P/E15.64 EPS next Y6.41 Insider Trans-51.97% Shs Float2.77B Perf Month1.77%
Income16.11B PEG3.65 EPS next Q1.45 Inst Own67.60% Short Float1.01% Perf Quarter0.81%
Sales71.88B P/S3.87 EPS this Y18.50% Inst Trans0.36% Short Ratio3.85 Perf Half Y1.51%
Book/sh24.14 P/B4.15 EPS next Y3.77% ROA12.20% Target Price109.59 Perf Year2.91%
Cash/sh11.29 P/C8.87 EPS next 5Y4.83% ROE22.00% 52W Range93.15 - 107.45 Perf YTD-2.79%
Dividend3.00 P/FCF- EPS past 5Y5.30% ROI18.40% 52W High-7.16% Beta0.61
Dividend %2.99% Quick Ratio2.10 Sales past 5Y3.70% Gross Margin69.50% 52W Low7.10% ATR1.07
Employees126500 Current Ratio2.40 Sales Q/Q-52.70% Oper. Margin28.10% RSI (14)51.59 Volatility0.91% 0.96%
OptionableYes Debt/Eq0.28 EPS Q/Q-49.10% Profit Margin22.40% Rel Volume0.72 Prev Close100.21
ShortableYes LT Debt/Eq0.22 EarningsJul 14 BMO Payout49.60% Avg Volume7.24M Price99.76
Recom2.50 SMA200.17% SMA500.28% SMA200-1.36% Volume1,192,811 Change-0.45%
May-21-15Reiterated Deutsche Bank Hold $106 → $110
Dec-08-14Reiterated RBC Capital Mkts Outperform $110 → $114
Jul-16-14Reiterated Deutsche Bank Hold $102 → $107
Apr-17-14Reiterated Argus Buy $104 → $116
Apr-16-14Reiterated RBC Capital Mkts Outperform $104 → $106
Jan-10-14Downgrade Barclays Overweight → Equal Weight $99
Jan-07-14Upgrade RBC Capital Mkts Sector Perform → Outperform $88 → $104
Dec-16-13Reiterated Deutsche Bank Hold $93 → $95
Jul-18-13Reiterated Argus Buy $96 → $104
Jul-17-13Reiterated Barclays Overweight $95 → $99
Jul-17-13Downgrade Deutsche Bank Buy → Hold $92 → $93
Apr-18-13Reiterated Argus Buy $80 → $96
Apr-15-13Reiterated Barclays Overweight $85 → $95
Apr-12-13Reiterated Deutsche Bank Buy $82 → $87
Mar-26-13Reiterated UBS Buy $81 → $87
Jan-11-13Reiterated UBS Buy $76 → $78
Jan-04-13Upgrade Deutsche Bank Hold → Buy $75 → $82
Nov-20-12Initiated Stifel Nicolaus Hold
Jul-18-12Reiterated RBC Capital Mkts Sector Perform $65 → $71
Apr-18-12Reiterated UBS Buy $71 → $70
Aug-02-15 08:00AM  5 Dividend Stocks for Your Portfolio at 24/7 Wall St.
Jul-31-15 04:32PM  JOHNSON & JOHNSON Files SEC form 10-Q, Quarterly Report
04:24PM  Ebola game changer?
01:00PM  A game changer for Ebola cure
09:57AM  PerkinElmer Beats Q2 Earnings and Revenues; Guides Up - Analyst Blog
09:23AM  Revisiting Harry Potter Stocks on His 35th Birthday - Analyst Blog
Jul-30-15 05:35PM  Brilinta? Brintellix? FDA warns of drug name mix-ups
02:45PM  MedTech Industry Stock Outlook - July/Aug 2015 - Zacks Analyst Interviews
02:45PM  MedTech Industry Stock Outlook - July/Aug 2015 - Industry Outlook
08:56AM  Kimberly-Clark Corp. Earnings Analysis: By the Numbers
08:07AM  The Best Deals in Low-Risk Stocks at Motley Fool
08:00AM  Cardinal Health Profit Rises 26% at The Wall Street Journal
12:01AM  IBM, CVS Will Use Watson Health Technology to Improve Patient Care at TheStreet
Jul-29-15 11:04AM  NuVasive Hits 7-Year High After Q2 Earnings Beat at Investor's Business Daily
09:06AM  Why Alcons Performance Was Weak in 2Q15
09:03AM  Bristol-Myers Squibb Co. Earnings Analysis: By the Numbers
06:00AM  The Top Drug Launches Of All Time at Forbes
Jul-28-15 11:46AM  Why Novartiss Revenues Declined Marginally
Jul-27-15 04:07PM  J&J Snack Foods posts 3Q profit
Jul-26-15 08:09AM  4 Great Stocks For Beginners at Motley Fool
08:00AM  Allergan To Buy Antidepressant Maker For $560 Million With Hopes Of Preventing Suicides at Forbes
Jul-25-15 10:03AM  Is Bristol-Myers Squibb Outpacing Johnson & Johnson? at Motley Fool
Jul-24-15 05:57PM  Bristol-Myers wins approval for 1st hepatitis C type 3 drug
03:12PM  Research and Markets: Global Wound Care Markets 2015 Business Wire
12:03PM  Boring Staples, Big Returns at Insider Monkey
11:44AM  Biogen Plunges On Slashed Guidance; AbbVie Q2 Mixed at Investor's Business Daily
Jul-23-15 05:48PM  Will AbbVie (ABBV) Surprise on Earnings Again in Q2? - Analyst Blog
Jul-22-15 10:25AM  4 Warren Buffett Dividend Stocks Jim Cramer Also Owns at TheStreet
09:30AM  Zacks Industry Outlook Highlights: AbbVie, Allergan, Pfizer, Juno and Johnson & Johnson - Press Releases
08:16AM  2015s Top 6 Big Pharma Headlines Thus Far at Motley Fool
Jul-21-15 02:52PM  Pharma Stock Outlook - July 2015 - Zacks Analyst Interviews
02:52PM  Pharma Stock Outlook - July 2015 - Industry Outlook
01:15PM  Novartis' Mixed Q2: Sandoz Booms, Alcon Struggles at Investor's Business Daily
12:21PM  Call of the day: Facebook
08:48AM  3 High-Dividend Pharmaceutical Stocks to Buy at TheStreet
Jul-20-15 08:31PM  Jim Cramer's 'Mad Money' Recap: Earnings Tsunami Heads Our Way at TheStreet
07:06PM  Cramer Remix: When to take a bite out of Apple at CNBC
06:35PM  Cramer: Johnson & Johnson needs to break up-NOW! at CNBC
06:25PM  JNJ could unlock 50% more value: Cramer
06:05PM  Who Doesn't Like Top Stocks With Big, Steady Payout? at Investor's Business Daily
11:40AM  Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2015 PR Newswire
09:30AM  The Zacks Analyst Blog Highlights: Intel, UnitedHealth Group, Johnson & Johnson, JPMorgan Chase and Goldman Sachs - Press Releases
Jul-19-15 01:05PM  You Won't Believe Which Consumer Products Company Spends the Most on Research & Development at Motley Fool
Jul-18-15 10:01AM  How To Invest In The Stock Market With Kevin O'Leary Of Shark Tank at Forbes
08:15AM  Johnson & Johnson Earnings Analysis: By the Numbers
Jul-17-15 06:27PM  The Long & Short (Term) Of The Pharmaceutical Sector
05:38PM  Utah defends contact lens price law for out-of-state buyers
04:02PM  Dow 30 Stock Roundup: Intel, UnitedHealth, JPMorgan, JNJ Beat - Analyst Blog
04:01PM  The 4 Stocks That Sank the DJIA on Friday at 24/7 Wall St.
10:33AM  Heres what CEOs said on this weeks earnings calls
Jul-16-15 01:45PM  J&J step closer to idled McNeil's plant reopening at
09:35AM  UBS Makes Summer Changes to Dividend Ruler Stocks Portfolio at 24/7 Wall St.
Jul-15-15 07:10PM  Yacktman Fund Reduces Stakes in Six of its Most Valuable Holdings
06:15PM  Cramer: Receptos perfect fit for Celgene
02:44PM  3 Questions Johnson & Johnson's Second-Quarter Results Answered at Motley Fool
01:57PM  Johnson & Johnson (JNJ) Stock Up, Seeks to Revive Non-Prescription Business at TheStreet
11:45AM  Here's Why No One Cares Anymore That Your Profit Beat Estimates at Bloomberg
11:28AM  US Stocks Rise 0.43%: JPM Surprises Markets, JNJ Beats Estimate
11:28AM  Picks Boosted by Johnson & Johnson Trends at
09:48AM  The Three Signs Of The Coming Greek Plague at Forbes
09:30AM  4 Healthcare ETFs to Buy as JNJ Beats Estimates - ETF News And Commentary
12:10AM  J&Js Nonprescription Business Could Soon Get a Lift at The Wall Street Journal
Jul-14-15 07:21PM  Cramer Remix: Wake up or you'll miss these stocks at CNBC
07:00PM  Cramer: Wake up or you'll miss these stocks
06:11PM  Cramer: Beware! Expensive earnings season mistakes at CNBC
05:29PM  Edited Transcript of JNJ earnings conference call or presentation 14-Jul-15 12:30pm GMT
05:05PM  US stocks post a 4th straight gain; Micron soars
03:29PM  Johnson & Johnson -- Moody's: J&J's 2Q2015 shows consistent growth, strong diversity at Moody's
03:08PM  Johnson & Johnson edges Street views with weak 2Q
02:30PM  Tuesday ETF Winners: Energy Leads As Nuclear Deal Announced at Investor's Business Daily
02:28PM  J&J's Nonprescription Business Could Soon Get a Lift at The Wall Street Journal
02:08PM  US stocks head for a 4th day of gains; Micron soars
01:14PM  Greece bans export of 25 drugs after pharmacists' supply warnings Reuters
12:47PM  Johnson And Johnson (JNJ) Earnings Report: Q2 2015 Conference Call Transcript at TheStreet
12:38PM  Johnson & Johnson second-quarter sales wilt on strong dollar, weak device sales
12:36PM  J&J 2nd-qtr sales wilt on strong dollar, weak device sales
12:20PM  Johnson & Johnson Earnings Beat Estimates Despite the Strong Dollar at TheStreet
12:07PM  Stocks Extend Rally as Crude Oil Prices Recover at TheStreet
11:43AM  Johnson & Johnson Earnings Top Estimates Despite Headwinds at TheStreet
11:25AM  Johnson & Johnson sales hit by 'biosimilar' competition at Financial Times
11:21AM  Stocks rising after retail sales report, earnings news
11:18AM  J&J Earnings Beat Views As Pharma Leads Way Again at Investor's Business Daily
11:14AM  Stocks Gain as Crude Recovers From Earlier Pressure at TheStreet
11:10AM  Stocks attempt gains as Street eyes data, earnings at CNBC
10:55AM  J&J Beats on Q2 Earnings, Raises 2015 Earnings Outlook - Analyst Blog
10:31AM  Stocks are slightly higher
10:28AM  Johnson & Johnson (JNJ) Sees Q2 Revenues, Profits Drop But Beats Expectations at Insider Monkey
10:24AM  J&J's merger and acquisition plans
09:59AM  Johnson & Johnson Sees Better Times Ahead Despite Dollar-Driven Declines at Motley Fool
09:46AM  A mixed start for stocks as investors focus on sales drop
09:39AM  J&J (JNJ) Beats on 2Q Earnings and Revenues - Tale of the Tape
09:38AM  Pisani's market open: What happened to retail?
09:38AM  Pharma Is A Standout For Johnson & Johnson Amid A Quarter Hit By Foreign Exchange at Forbes
09:21AM  Johnson & Johnson (JNJ) Stock Falls Despite Earnings Beat at TheStreet
09:09AM  Stock Futures Mixed as Retail Sales Drop, Oil Prices Slide at TheStreet
09:06AM  Johnson & Johnson sales down, but profits up at USA TODAY
09:04AM  J&J Tops Estimates as Drug Sales Expand Before Dollar Effect
09:00AM  JPMorgan Chase, J&J and Wells Fargo profit; Micron Technology bid
08:50AM  Cramer: US dollar too strong
08:47AM  Johnson & Johnson tops Street 2Q forecasts
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand name; oral care products under the LISTERINE brand name; skin care products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, LUBRIDERM, NEUTROGENA, and RoC brand names; women's health products, such as sanitary pads under the STAYFREE and CAREFREE, and o.b. tampon brand names; wound care products, including adhesive bandages and first aid products under the BAND-AID and NEOSPORIN brand names; and nutritional products comprising no calorie sweetener under the SPLENDA brand name. This segment also offers over-the-counter medicines, including acetaminophen products under the TYLENOL brand name; cold, flu, and allergy products under the SUDAFED brand name; allergy products under the BENADRYL and ZYRTEC brand names; ibuprofen products under the MOTRIN IB brand name; and heartburn products under the PEPCID brand name. The Pharmaceutical segment provides various products in the areas of immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment offers orthopaedic, and trauma and neurological products; general surgery, and biosurgical and energy products; products to treat cardiovascular disease; infection prevention products; diagnostics products; blood glucose monitoring and insulin delivery products; and disposable contact lenses. The company distributes its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use in the professional fields by physicians, nurses, hospitals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PRINCE CHARLESDirectorJun 02Buy99.222,500248,05023,145Jun 03 05:20 PM
Stoffels PaulusChief Scientific OfficerApr 28Option Exercise64.43228,68314,733,404281,723Apr 30 04:56 PM
Stoffels PaulusChief Scientific OfficerApr 28Sale100.73187,25018,862,14294,473Apr 30 04:56 PM
Fasolo PeterVP, Global Human ResourcesMar 05Option Exercise65.37115,3077,537,619147,895Mar 09 05:14 PM
Fasolo PeterVP, Global Human ResourcesMar 05Sale102.40115,30711,807,86332,588Mar 09 05:14 PM
Stoffels PaulusChief Scientific OfficerFeb 09Option Exercise0.0029,073064,647Feb 11 08:16 PM
Caruso Dominic JVP, Finance; CFOFeb 09Option Exercise0.0031,5370101,324Feb 11 08:16 PM
Fasolo PeterVP, Global Human ResourcesFeb 09Option Exercise0.0020,935042,109Feb 11 08:16 PM
Gorsky AlexChairman, CEOFeb 09Option Exercise0.0042,1120130,173Feb 11 08:17 PM
COSGROVE STEPHEN JCorporate ControllerJan 16Option Exercise0.0011,1080101,402Jan 21 05:48 PM
Ullmann Michael HVP, General CounselJan 16Option Exercise0.008,949075,628Jan 21 05:48 PM
Caruso Dominic JVP, Finance; CFOJan 16Option Exercise0.0012,615074,216Jan 21 05:48 PM
Gorsky AlexChairman, CEOJan 16Option Exercise0.0016,845094,425Jan 21 05:48 PM
Stoffels PaulusChief Scientific OfficerJan 16Option Exercise0.0011,629039,539Jan 21 05:48 PM
Fasolo PeterVP, Global Human ResourcesJan 16Option Exercise0.008,374024,336Jan 21 05:48 PM
PETERSON SANDRA EGroup Worldwide ChairmanDec 17Option Exercise0.0021,689031,210Dec 19 04:37 PM
JOHNSON & JOHNSON10% OwnerNov 12Buy18.0040,000720,0003,077,005Nov 12 03:06 PM
COSGROVE STEPHEN JCorporate ControllerNov 05Option Exercise66.182,490164,78892,784Nov 07 04:49 PM
COSGROVE STEPHEN JCorporate ControllerNov 05Sale108.552,490270,29390,294Nov 07 04:49 PM
CULLEN JAMESDirectorSep 10Sale104.122,446254,6721,489Sep 11 02:19 PM
Caruso Dominic JVP, Finance; CFOAug 21Option Exercise66.1830,0001,985,40091,600Aug 25 04:35 PM
Caruso Dominic JVP, Finance; CFOAug 21Sale104.3030,0003,129,06961,600Aug 25 04:35 PM